Flosonics Medical announced that the Mount Sinai Hospital has adopted its FloPatch device, the first deployment of this wearable doppler ultrasound on the US East Coast.
The FloPatch is designed to enhance patient safety by providing intensive care unit (ICU) teams with rapid, data-driven insights to prevent fluid overload during post-surgical care.
It is a non-invasive device approved by the US Food and Drug Administration (FDA), that allows ICU clinicians to conduct quick and repeatable hemodynamic assessments.
The device helps in guiding intravenous (IV) fluid management, where traditional fluid boluses may lead to complications if patients are not fluid responsive.
FloPatch delivers real-time blood flow data at the bedside in under three minutes, enabling more precise and timely clinical decisions.
Flosonics Medical co-founder and chief medical officer Jon-Emile Kenny said: “Critical care ultrasound for targeted intravenous volume management is now a Society recommendation, but widespread application is limited by time, training, and inconsistency.
“We built FloPatch to make ultrasound best practices available not only to physicians, but to nurses, nurse practitioners, physician assistants, and others involved in frontline decision-making.
“As the first hospital on the East Coast to adopt wearable ultrasound technology, Mount Sinai strengthens its reputation of leadership and innovation in precision medicine.”
Founded in 2015, Flosonics Medical is a medical device company focused on advancing patient care through advanced ultrasound technology and clinical research.
Since its launch in April 2025, FloPatch has facilitated more precise fluid therapy at Mount Sinai, shifting from standardised care to personalised treatment based on real-time data.
Initial data from Mount Sinai indicates that 42% of patients assessed with FloPatch were unresponsive to fluids, allowing clinicians to tailor treatments more effectively.
The adoption of FloPatch by Mount Sinai represents a significant shift towards precision medicine in critical care.
As the first hospital to implement this technology in its surgical and transplant ICUs, Mount Sinai is setting a new standard for personalised fluid management.
Mount Sinai Icahn School of Medicine surgery and medicine professor and Mount Sinai Hospital transplant ICU director John Oropello said: “The wireless ultrasound device addresses a longstanding need in critical care for accessible and repeatable assessments to understand a patient’s fluid responsiveness at the bedside.
“It allows our team to make timely, physiologically guided decisions in complex, high-acuity situations.”
